Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ULK1 | O75385 | 2/20 | 0.53 |
| ▸ | INSR | P06213 | 5/20 | 0.51 |
| ▸ | EGFR | P00533 | 4/20 | 0.51 |
| ▸ | PTK2 | Q05397 | 3/20 | 0.51 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.51 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.51 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.51 |
| ▸ | IGF1R | P08069 | 2/20 | 0.51 |
| ▸ | PTK2B | Q14289 | 2/20 | 0.51 |
| ▸ | PKMYT1 | Q99640 | 1/20 | 0.51 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.51 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.50 |
| ▸ | ALK | Q9UM73 | 6/20 | 0.49 |
| ▸ | MET | P08581 | 6/20 | 0.49 |
| ▸ | CDK2 | P24941 | 2/20 | 0.49 |
| ▸ | CDC7 | O00311 | 1/20 | 0.49 |
| ▸ | PLK4 | O00444 | 1/20 | 0.49 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.49 |
| ▸ | AURKA | O14965 | 1/20 | 0.49 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12729763 | 0.93 | PTK2 (0.61) | ULK1INSREGFRPTK2MAPK8 | |
| SCHEMBL12729784 | 0.92 | INSR (0.52) | ULK1INSREGFRPTK2MAPK8 | |
| SCHEMBL12729786 | 0.90 | ALK (0.57) | ULK1INSREGFRPTK2MAPK8 | |
| SCHEMBL12729791 | 0.87 | EGFR (0.54) | ULK1INSREGFRPTK2MAPK8 | |
| SCHEMBL12729789 | 0.87 | EGFR (0.54) | ULK1INSREGFRPTK2MAPK8 | |
| SCHEMBL12780401 | 0.84 | PLK1 (0.47) | INSREGFRPTK2IGF1RPKMYT1 | |
| SCHEMBL1911938 | 0.83 | ALK (0.64) | INSREGFRPTK2MAPK8MAPK9 | |
| SCHEMBL12780190 | 0.82 | EGFR (0.48) | INSREGFRPTK2IGF1RPKMYT1 | |
| SCHEMBL1912045 | 0.80 | MAPK9 (0.72) | ULK1INSREGFRPTK2MAPK8 | |
| SCHEMBL12780208 | 0.79 | ALK (0.46) | INSREGFRPTK2MAPK8MAPK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7893074-B2 | inhibition of focal adhesion kinase or/and IGF-1 Receptor; for example: 2-[2-(2,5-Dimethoxy-phenylamino)-5-nitro-pyrimidin-4-ylamino]-N-methyl-benzenesulfonamide | NOVARTIS AG (CH) | 2011-02-22 | — | — | US | disclosed |
| US-20080132504-A1 | 2, 4-Pyrimidinediamines Useful In The Treatment Of Neoplastic Diseases, Inflammatory And Immune System Disorders | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2008-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132504-A1 | 2, 4-Pyrimidinediamines Useful In The Treatment Of Neoplastic Diseases, Inflammatory And Immune System Disorders | TYMS, TYMP, DPYD | ULK1 2458/4885INSR 2899/4885EGFR 2285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.